Format

Send to

Choose Destination
See comment in PubMed Commons below
Gynecol Oncol. 2014 Jul;134(1):190-5. doi: 10.1016/j.ygyno.2014.04.060. Epub 2014 May 5.

The therapeutic significance of aromatase inhibitors in endometrial carcinoma.

Author information

1
Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
2
Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China. Electronic address: zhuyuanxi1963@gmail.com.
3
Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, People's Republic of China. Electronic address: fengxiaxue1962@gmail.com.

Abstract

OBJECTIVE:

To review recent studies about the application of aromatase inhibitors in endometrial carcinoma and the benefits and challenges of aromatase inhibitors in this regard.

METHODS:

Relevant studies and manuscripts were searched for in Pubmed using the following terms, either alone or in combination: aromatase, aromatase inhibitors, letrozole, anastrozole, endometrial cancer, breast cancer, endocrine, therapy, and side effects.

RESULTS:

Endometrial carcinoma is one of the most pervasive gynecological malignancies. Type I endometrial carcinoma is estrogen-dependent. Recent studies have demonstrated that aromatase inhibitors, which interfere with estrogen biosynthesis by inhibiting the activity of aromatase, can be used to treat endometrial carcinoma and its precancerous lesions to some extent. In early-stage endometrial carcinoma or atypical hyperplasia, a precancerous lesion of endometrial carcinoma, the effects of aromatase inhibitors were promising. However, in advanced or recurrent endometrial carcinoma, the application of aromatase inhibitors cannot solve the problem evidently. In addition, these inhibitors have limitations, like side effects and drug resistance. The need for a new generation of inhibitors with higher specificity and fewer side effects should be studied further.

CONCLUSIONS:

Aromatase inhibitors show promise in the therapy of endometrial carcinoma, especially the early stage. Further studies should be conducted to develop next-generation aromatase inhibitors with higher specificity and fewer side effects.

KEYWORDS:

Aromatase; Aromatase inhibitors; Endometrial carcinoma; Estrogen; Therapy

PMID:
24811574
DOI:
10.1016/j.ygyno.2014.04.060
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center